Kyverna Locks In Commercial Manufacturing for CAR-T Therapy Ahead of BLA Completion
KYTX has more than doubled off its 52-week low of $2.8.
Summary
Kyverna Therapeutics signed a five-year commercial and clinical supply agreement with ElevateBio for its lead CAR-T candidate, miv-cel. The deal secures scalable manufacturing for potential U.S. launches in stiff person syndrome and myasthenia gravis, with the rolling BLA submission on track for completion in Q4 2026. This follows the BLA initiation in May and recent executive hires, underscoring the company's push toward commercialization. The agreement de-risks a critical operational bottleneck as Kyverna approaches its first potential FDA approval. With a $450M market cap and a $100M ATM in place, reliable manufacturing capacity is a tangible step toward revenue generation.
At the time of this announcement, KYTX was trading at $7.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $450.5M. The 52-week trading range was $2.80 to $13.67. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.